Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:alsoKnownAs |
gptkb:QazCovid-in
|
| gptkbp:category |
gptkb:COVID-19_pandemic_in_Kazakhstan
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2021)
|
| gptkbp:composition |
inactivated SARS-CoV-2 virus
|
| gptkbp:countryOfOrigin |
gptkb:Kazakhstan
|
| gptkbp:developedBy |
gptkb:Research_Institute_for_Biological_Safety_Problems
|
| gptkbp:doseInterval |
21 days
|
| gptkbp:emergencyServices |
gptkb:Kazakhstan
|
| gptkbp:firstReleased |
2021
|
| https://www.w3.org/2000/01/rdf-schema#label |
QazVac
|
| gptkbp:numberOfDoses |
2
|
| gptkbp:publicAvailability |
April 2021
|
| gptkbp:status |
in use in Kazakhstan
|
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
vaccine
|
| gptkbp:WHOStatus |
not listed for emergency use by WHO (as of 2023)
|
| gptkbp:bfsParent |
gptkb:COVID-19_pandemic_response_in_Kazakhstan
|
| gptkbp:bfsLayer |
6
|